Medicare to Begin Covering Weight-Loss Drugs Including GLP-1s Starting July 1

1-Minute Brief

Expanded Medicare coverage may affect access, costs, and treatment options for millions of older Americans seeking obesity medications.

Key Facts

• Medicare beneficiaries will have access to weight-loss drugs for the first time starting July 1.
• Novo Nordisk is preparing for the CMS bridge program, which will impact Medicare beneficiaries' access to obesity treatments.
• Company executives are uncertain if patient volume will increase immediately or gradually after the program's rollout.
• Novo Nordisk is working to educate healthcare providers and pharmacists about patient eligibility for these treatments.
• Beneficiaries are advised to consider unique factors related to Medicare coverage of weight-loss drugs.

What Happened

Medicare will begin covering certain weight-loss drugs, including GLP-1 medications, starting July 1. Novo Nordisk is preparing for this change and providing education to healthcare professionals.

Why It Matters

This policy change could expand access to obesity treatments for millions of older Americans, potentially influencing health outcomes and the pharmaceutical market.

What's Next

Stakeholders are monitoring how quickly patient demand will grow and how effectively healthcare providers adapt to the new coverage rules.